5-Amino-1MQ is a small molecule NNMT inhibitor used for fat loss — taken orally in capsule form, not by injection. It is not a peptide in the traditional sense but is commonly grouped with research peptides in the metabolic optimization space.
Research-context information only. 5-Amino-1MQ is an investigational research compound not approved by any regulatory body. Protocols, doses, and reactions reported below come from preclinical animal research and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
No human clinical trials exist. All protocols are based on preclinical animal data and community experience. This is not medical advice.
5-Amino-1MQ Dosing Table
Match your vial size below — reconstitution and dose math update automatically.
Reconstitute: add 2 mL of bacteriostatic water to the 50 mg vial. Resulting concentration: 25 mg/mL.
Dose
Syringe units
mL volume
Schedule
50 mg
200 units
2 mL
Daily oralStarter (full vial)
100 mg
400 units
4 mL
Daily oralStandard (2 vials)
150 mg
600 units
6 mL
Daily oralMax (3 vials)
50 mg200 units · 2 mL
Daily oral
Starter (full vial)
100 mg400 units · 4 mL
Daily oral
Standard (2 vials)
150 mg600 units · 6 mL
Daily oral
Max (3 vials)
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.
Reconstitute: add 1 mL of bacteriostatic water to the 10 mg vial. Resulting concentration: 10 mg/mL.
Dose
Syringe units
mL volume
Schedule
10 mg
100 units
1 mL
Daily oralStarter
50 mg
500 units
5 mL
Daily oralRequires 5 vials
10 mg100 units · 1 mL
Daily oral
Starter
50 mg500 units · 5 mL
Daily oral
Requires 5 vials
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.
Quick Reference: Community Protocol
Parameter
Community Protocol
Route
Oral (capsule)
Starting dose
50 mg/day for 1-2 weeks
Standard dose
100-150 mg/day
Timing
Morning, with or without food
Frequency
Once daily
Cycle
8-12 weeks on, 4-8 weeks off
Storage
Room temperature, cool dry place
Community protocols describe a 50 mg/day starting phase lasting 1-2 weeks, escalating to 100-150 mg/day based on tolerance. Most reported protocols settle at 100 mg as the maintenance level. No reconstitution needed — oral capsule.
Cycling Details
The 8-12 week on / 4-8 week off cycle accounts for the absence of long-term human safety data. Community protocols describe gradual dose escalation rather than a loading phase.
Week 1-2: 50 mg daily to assess GI tolerance, energy changes, and side effects. Week 3-12: Increase to 100-150 mg daily if well-tolerated. The off period allows assessment of sustained metabolic benefits after discontinuation.
Morning dosing is preferred to align with peak metabolic activity. Community protocols describe consistent daily timing for sustained NNMT inhibition.
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
Routes of Administration
Oral (only route): Capsule form, typically available in 50 mg capsules. High oral bioavailability — Caco-2 cell assays showed excellent passive and active membrane transport with no detectable efflux (Neelakantan et al., 2018). Stable at room temperature. No reconstitution, syringes, or refrigeration needed.
Not an injectable. Unlike most compounds on this site, 5-Amino-1MQ is a small molecule designed for oral delivery.
Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.
Where These Numbers Come From
5-Amino-1MQ dosing is entirely community-derived, extrapolated from preclinical animal research. No human clinical trials have been conducted.
Key Preclinical Study (Neelakantan et al., 2018): Treatment in diet-induced obese mice produced progressive body weight loss, reduced white adipose tissue mass and adipocyte size, decreased total cholesterol, and no changes in food intake — effects were metabolic, not appetite-driven. The study used 20 mg/kg SC three times daily in mice.
NNMT as Target (Kraus et al., 2014): NNMT knockdown in white adipose tissue and liver protected against diet-induced obesity by increasing cellular energy expenditure. This established the mechanistic rationale for NNMT inhibition.
Combined Approaches (Neelakantan et al., 2022): NNMT inhibition with reduced-calorie diet produced dramatic adiposity reduction in DIO mice, normalizing metabolic parameters and establishing a distinct gut microbiome.
Community oral doses (50-150 mg daily) are based on allometric scaling from mouse studies, oral bioavailability data, and several years of community trial and error.
Complementary mechanisms — metabolic enhancement plus appetite suppression. Community sources note that combining multiple metabolic compounds can amplify stimulant-like effects.
Side Effects & Safety
Mild GI discomfort — most common, usually transient in the first week
Slight stimulant effect — increased energy/alertness, especially early on
Headaches — occasional, typically mild and dose-related
Mild insomnia — if taken too late in the day
No human clinical safety data — all safety information from preclinical studies and community reports
No liver toxicity observed in animal studies at therapeutic doses
Unknown drug interactions — theoretically could interact with NAD+-dependent pathways
Core Supplies for This Protocol
The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking.
What doses do community sources and preclinical research report for 5-Amino-1MQ?
Community-reported starting doses are 50 mg/day for 1-2 weeks, escalating to 100-150 mg/day. Most reported protocols settle at 100 mg for maintenance. Reported cycle lengths are 8-12 weeks on, 4-8 weeks off.
Is 5-Amino-1MQ taken orally or by injection?
5-Amino-1MQ is taken orally in capsule form. Unlike most research peptides, it has high oral bioavailability due to excellent membrane permeability demonstrated in Caco-2 cell assays. No reconstitution or injection needed.
How long should a 5-Amino-1MQ cycle last?
Community protocols typically run 8-12 weeks on, followed by 4-8 weeks off. This cycling approach accounts for the lack of long-term human safety data.
Does 5-Amino-1MQ suppress appetite?
No — 5-Amino-1MQ does not work through appetite suppression. It targets NNMT enzyme activity to increase cellular energy expenditure and NAD+ availability in adipose tissue, promoting fat metabolism rather than reducing food intake.
What stacking protocols are documented for 5-Amino-1MQ?
Community sources document stacking with MOTS-c for mitochondrial support and tesofensine for complementary appetite suppression. Documented protocols introduce each compound individually before combining.
What are the side effects of 5-Amino-1MQ?
Community reports include mild GI discomfort, occasional headaches, and slight stimulant-like effects. No human clinical trials exist, so long-term safety is unknown.
